Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade - Archive ouverte HAL
Article Dans Une Revue Rheumatology and Therapy Année : 2021

Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade

Résumé

It is unclear whether polymyalgia rheumatica (PMR) should be considered an inflammatory disease or an autoimmune disease.

Domaines

Immunologie

Geneviève Michel  : Connectez-vous pour contacter le contributeur

https://hal.science/hal-03205677

Soumis le : jeudi 22 avril 2021-14:53:00

Dernière modification le : jeudi 13 avril 2023-13:30:07

Consulter le texte intégral

Dates et versions

hal-03205677 , version 1 (22-04-2021)

Identifiants

Citer

Guillermo Carvajal Alegria, Divi Cornec, Yves Renaudineau, Alain Saraux, Valérie Devauchelle-Pensec. Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade. Rheumatology and Therapy, 2021, ⟨10.1007/s40744-021-00299-8⟩. ⟨hal-03205677⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM UNIV-BREST IMMUNO IBSAM
35 Consultations
0 Téléchargements

Altmetric

Partager

More